Q-omics provides the consensus-scored RAD17P2 profile across patient tissues and cancer cell-line models. RAD17P2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RAD17P2 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, RAD17P2 RNA expression shows 11,312 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KICH, and LSCC as cancer lineages where RAD17P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD17P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD17P2 survival associations across molecular data types. RAD17P2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD17P2 RNA expression–survival associations across cancer types. High RAD17P2 expression shows unfavorable associations in LUSC, MESO and ACC, but favorable associations in UCS, BLCA and PAAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RAD17P2 RNA expression.
This table summarizes RAD17P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RAD17P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD17P2 shows lower tumor expression in KICH, BRCA, KIRC, LUSC and THCA and higher tumor expression in HNSC. The KICH box plot shows higher RAD17P2 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .013).
This table shows molecular features associated with RAD17P2 in patient tissues and cancer cell lines. In patient samples, RAD17P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
